{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:54Z","timestamp":1790913714069,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.03.014","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T12:11:47Z","timestamp":1439899907000},"page":"S114-S119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S","title":["Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"15","author":[{"given":"Santosh V.","family":"Chikkodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shano","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal Kant","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.03.014_bib1","article-title":"Chronic myeloid leukaemia","author":"Apperley","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.03.014_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.03.014_bib3","article-title":"Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points","author":"Lapusan","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.03.014_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(07)61510-4","article-title":"Chronic myeloid leukaemia in India","volume":"370","author":"Malhotra","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.03.014_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0971-5851.123728","article-title":"A\u00a0short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh","volume":"34","author":"Malhotra","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2015.03.014_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0971-5916.93423","article-title":"Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India","volume":"135","author":"Anand","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.clml.2015.03.014_bib7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1472-6963-13-304","article-title":"Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program","volume":"13","author":"Tekinturhan","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clml.2015.03.014_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.014_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00277-012-1468-4","article-title":"Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns","volume":"91","author":"L\u00f3pez-Jorge","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.03.014_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2141.2002.03705.x","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.03.014_bib11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.03.014_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.03.014_bib13","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.014_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.23707","article-title":"BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.03.014_bib15","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha","year":"2013","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015001196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015001196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T01:52:44Z","timestamp":1537408364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015001196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":15,"alternative-id":["S2152265015001196"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.03.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}